EG:NYSEEverest Group, Ltd. Analysis
Data as of 2026-03-13 - not real-time
$321.67
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Everest Group (EG) trades around $321.67, well below its DCF‑derived fair value of $741.58, implying a material valuation gap. The stock’s trailing P/E of 8.5 is less than half the industry average of 16.4, reinforcing the undervaluation narrative. A dividend yield of 2.48% with a modest payout ratio of 21% suggests the dividend is sustainable and attractive for income‑focused investors. Recent news highlights a $2.00 per share dividend declaration, $150 million of restructuring charges aimed at sharpening the wholesale specialty focus, and accelerated share buybacks, all of which support the positive earnings outlook. Fundamentals show stable operating cash flow of $3.07 billion, low leverage (debt‑to‑equity 24.5%), and a low beta of 0.48, indicating limited market volatility. However, revenue contracted by 2.9% YoY and free cash flow remains negative, reflecting ongoing transformation costs.
Technical indicators are mixed: RSI at 37 points to near‑oversold conditions, while the MACD remains bearish and the price sits just above the $317 support level, below the $348 resistance. Volume is stable, and the 30‑day volatility of 18.8% is moderate for the sector. The “Greed” sentiment on the Fear & Greed Index (72.8) aligns with the market’s appetite for undervalued, dividend‑paying insurers. Overall, the combination of strong valuation upside, solid dividend profile, and manageable risk metrics positions EG as a compelling buy for investors with short‑ to long‑term horizons.
Technical indicators are mixed: RSI at 37 points to near‑oversold conditions, while the MACD remains bearish and the price sits just above the $317 support level, below the $348 resistance. Volume is stable, and the 30‑day volatility of 18.8% is moderate for the sector. The “Greed” sentiment on the Fear & Greed Index (72.8) aligns with the market’s appetite for undervalued, dividend‑paying insurers. Overall, the combination of strong valuation upside, solid dividend profile, and manageable risk metrics positions EG as a compelling buy for investors with short‑ to long‑term horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bearish MACD but RSI near oversold suggests limited downside
- Price close to support at $317 provides a cushion
- Strong dividend yield and low payout ratio
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Valuation upside of ~13% to target price
- Restructuring and buyback program expected to improve earnings
- Low beta and moderate volatility support stable price appreciation
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Significant valuation gap versus DCF fair value
- Sustainable dividend and low leverage enhance total return
- Strategic focus on specialty lines and continued buybacks
Key Metrics & Analysis
Financial Health
Revenue Growth-2.90%
Profit Margin9.07%
P/E Ratio8.5
ROE10.85%
ROA2.22%
Debt/Equity24.48
P/B Ratio0.8
Op. Cash Flow$3.1B
Free Cash Flow$-22327625728
Industry P/E16.4
Technical Analysis
TrendNeutral
RSI37.1
Support$317.02
Resistance$348.31
MA 20$334.92
MA 50$331.16
MA 200$333.97
MACDBearish
VolumeStable
Fear & Greed Index72.82
Valuation
Fair Value$741.58
Target Price$364.53
Upside/Downside13.33%
GradeUndervalued
TypeValue
Dividend Yield2.48%
Risk Assessment
Beta0.48
Volatility18.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.